Early use of interferon β in patients with multiple sclerosis

International Journal of Clinical Practice, Supplement

Volumn , Issue 131, 2002, Pages 17-22

  Bosley, E B ^a   Capildeo, R ^a  

^a BASILDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

AXONAL INJURY; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; FEVER; HEADACHE; HUMAN; MULTIPLE SCLEROSIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MULTIPLE SCLEROSIS; SYRINGES; TIME FACTORS;

EID: 0036760483     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399.
2. Trapp BD, Peterson J, Ransohoff RM et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
3. De Stefano N, Narayanan S, Francis GS et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70.
4. Liu C, Edwards S, Gong Q et al. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 66: 323-330.
5. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13: 119-146.
6. Filippi M, Horsfield MA, Morrissey SP et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44: 635-641.
7. O'Riordan JI, Thompson AJ, Kingsley DP et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: A 10-year follow-up. Brain 1998; 121: 495-503.
8. National Multiple Sclerosis Society. Disease Management Consensus Statement, 1998.
9. Oger J, Freedman M. Consensus statement of the Canadian MS Clinics Network on the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci 1999; 26: 274-275.
10. Freedman MS, Blumhardt LD, Brochet B et al. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002; 8: 19-23.
11. Rothuizen LE, Buclin T, Spertini F et al. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999; 99: 131-141.
12. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-153.
13. Leppert D, Waubant E, Burk MR et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-852.
14. Boutros T, Croze E, Yong VW. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J Neurochem 1997; 69: 939-946.
15. Rudick RA, Ransohoff RM, Peppler R et al. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-627.
16. Abreu SL, Tondreau J, Levine S, Sowinski R. Inhibition of passive localized experimental allergic encephalomyelitis by interferon. Int Arch Allergy Appl Immunol 1983; 72: 30-33.
17. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996; 64: 91-100.
18. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661.
19. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667.
20. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
21. Simon JH, Jacobs LD, Campion M et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1998; 43: 79-87.
22. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. PRISMS (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504.
23. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. PRISMS (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Ann Neurol 1999; 46: 197-206.
24. Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS study. The Once Weekly Interferon for MS Study Group. Neurology 1999; 53: 679-686.
25. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
26. Panitch H, Goodin S, Francis G et al. Randomized comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. Neurology 2002; in press.
27. Durelli L, Ferrero B, Ghezzi A et al. The Independent Comparison of Interferon (INCOMIN) Trial: A multicenter randomized trial comparing clinical and MRI efficacy of IFN beta-1a and beta-1b in multiple sclerosis. Neurology 2001; 56(Suppl 3): A148.